Investor Relations

Company Profile

REVA Medical, Inc. ("REVA" or the "Company") is a medical device company that has developed a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s Fantom® scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations.

The Company enrolled patients in a pivotal clinical trial of the Fantom scaffold between March 2015 and March 2016. The trial was conducted at 28 clinical sites in eight countries outside of the United States, and included two sets of patients. 117 patients were enrolled in Cohort A of the trial and 123 patients in Cohort B, for total trial enrollment of 240 patients. Data from patients enrolled in the pivotal clinical trial were used to support an application for European CE Marking in early August 2016. REVA received CE Mark approval for the Fantom scaffold in April 2017. CE Marking allows for commercial sales in Europe and other countries that recognise the mark. With the approval, REVA will commence selling in selected centers in Europe during Q2 of this year.

REVA is a Delaware corporation with its corporate headquarters located in San Diego, California. REVA securities are traded on the Australian Securities Exchange ("ASX") under the symbol RVA. REVA’s international ticker symbol is RVA.AX. Its securities trade in the form of CHESS Depositary Interests ("CDIs"). The Company is also registered with the United States Securities and Exchange Commission (“SEC”), however its securities are currently not traded on any U.S. exchange. REVA has announced plans to pursue a listing of its securities on NASDAQ or another U.S. exchange, with the goal to be accepted for listing no later than June 30, 2017.

Key Investor Facts

Trading Exchange

Australian Securities Exchange (“ASX”)

Australian Ticker Symbol

RVA

International Ticker Symbol

RVA.AX

Ratio of CDIs to shares of common stock

1:10

Number of CDIs outstanding*

428,514,770

Number of shares of common stock outstanding*

42,851,477

Australian Registered Body Number (ARBN)

146 505 777

* As of February 15, 2017